APIM Therapeutics is developing first-in-class PCNA-targeting therapeutics designed to improve cancer treatment by selectively disrupting cellular stress responses. Our clinical-stage lead candidate, ATX-101, and our next-generation pipeline offer opportunities across multiple oncology indications.
We welcome discussions with pharmaceutical and biotechnology companies, academic institutions and investors regarding strategic collaborations, licensing, co-development and regional partnering opportunities.
For business development and partnering enquiries, please contact:
Kostas Alevizopoulos PhD.
Chief Executive Officer
+47 73 204540
This email address is being protected from spambots. You need JavaScript enabled to view it.